DOCSLIB.ORG

Psychotropic Drugs: Sedatives/Hypnotics, Antidepressants, and Antipsychotics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Psychotropic Drugs: Sedatives/Hypnotics, Antidepressants, and Antipsychotics PSYCHOTROPIC DRUGS: SEDATIVES/HYPNOTICS, ANTIDEPRESSANTS, AND ANTIPSYCHOTICS INSTIs NNRTIs PIs RTI xBICTEGRAVIR xELVITEGRAVIR/ x DORAVIRINE x EFAVIRENZ xATAZANAVIR • TENOFOVIR • TENOFOVIR (Biktarvy) COBICISTAT (Pifeltro, (Sustiva, Atripla) (Reyataz/Norvir, ALAFENAMIDE, DISOPROXIL, TDF (Stribild, Genvoya) Delstrigo) Evotaz) TAF (Descovy, (Viread,Truvada, DOLUTEGRAVIR ETRAVIRINE x x Biktarvy, Genvoya, Atripla, Complera, (Tivicay, Triumeq, RILPIVIRINE (Intelence) DARUNAVIR x x Odefsey, Symtuza) Delstrigo, Stribild) Juluca) (Edurant, (Prezista/Norvir, x NEVIRAPINE Complera, Prezcobix, x RALTEGRAVIR (Viramune) •ABACAVIR (Kivexa, Odefsey, Juluca) Symtuza) (Isentress) Ziagen, Triumeq) xLOPINAVIR (Kaletra) SEDATIVES/HYPNOTICS xLorazepam, oxazepam, temazepam xAlprazolam, Potential for n Potential for p Potential for n bromazepam, benzodiazepine benzodiazepine benzodiazepine buspirone, clonazepam, estazolam, flurazepam, diazepam, nitrazepam, zolpidem, zopiclone xMidazolam, Potential for n Potential for p Potential for n triazolam benzodiazepine benzodiazepine benzodiazepine PSYCHOTROPICS INSTIs NNRTIs PIs RTI xBICTEGRAVIR xELVITEGRAVIR/ x DORAVIRINE x EFAVIRENZ xATAZANAVIR • TENOFOVIR • TENOFOVIR (Biktarvy) COBICISTAT (Pifeltro, (Sustiva, Atripla) (Reyataz/Norvir, ALAFENAMIDE, DISOPROXIL, TDF (Stribild, Genvoya) Delstrigo) Evotaz) TAF (Descovy, (Viread,Truvada, DOLUTEGRAVIR ETRAVIRINE x x Biktarvy, Genvoya, Atripla, Complera, (Tivicay, Triumeq, RILPIVIRINE (Intelence) DARUNAVIR x x Odefsey, Symtuza) Delstrigo, Stribild) Juluca) (Edurant, (Prezista/Norvir, x NEVIRAPINE Complera, Prezcobix, x RALTEGRAVIR (Viramune) •ABACAVIR (Kivexa, Odefsey, Juluca) Symtuza) (Isentress) Ziagen, Triumeq) xLOPINAVIR (Kaletra) ANTIDEPRESSANTS xMost TCAs, duloxetine xBupropion Etravirine may be Cobicistat-boosted used without dose PIs: may be used adjustment without dose adjustment Potential for p Ritonavir-boosted bupropion PIs: potential for p (efavirenz, bupropion nevirapine) xSt. John’s wort raltegravir WŽƚĞŶƚŝĂůĨŽƌљ WŽƚĞŶƚŝĂůĨŽƌљ WŽƚĞŶƚŝĂůĨŽƌљ WŽƚĞŶƚŝĂůĨŽƌљW/Ɛ WŽƚĞŶƚŝĂůĨŽƌљd& elvitegravir and TAF NNRTIs NNRTIs јĚŽůƵƚĞŐƌĂǀŝƌϱϬ *including Juluca mg BID bictegravir xMost SSRIs Potential for n WŽƚĞŶƚŝĂůĨŽƌљ Potential for n (citalopram, antidepressant antidepressant antidepressant escitalopram, PSYCHOTROPICS INSTIs NNRTIs PIs RTI xBICTEGRAVIR xELVITEGRAVIR/ x DORAVIRINE x EFAVIRENZ xATAZANAVIR • TENOFOVIR • TENOFOVIR (Biktarvy) COBICISTAT (Pifeltro, (Sustiva, Atripla) (Reyataz/Norvir, ALAFENAMIDE, DISOPROXIL, TDF (Stribild, Genvoya) Delstrigo) Evotaz) TAF (Descovy, (Viread,Truvada, DOLUTEGRAVIR ETRAVIRINE x x Biktarvy, Genvoya, Atripla, Complera, (Tivicay, Triumeq, RILPIVIRINE (Intelence) DARUNAVIR x x Odefsey, Symtuza) Delstrigo, Stribild) Juluca) (Edurant, (Prezista/Norvir, x NEVIRAPINE Complera, Prezcobix, x RALTEGRAVIR (Viramune) •ABACAVIR (Kivexa, Odefsey, Juluca) Symtuza) (Isentress) Ziagen, Triumeq) xLOPINAVIR (Kaletra) fluoxetine, sertraline), venlafaxine, desvenlafaxine, trazodone, reboxetine, mirtazapine ANTIP SYCHOTICS xAripiprazole, Potential for n WŽƚĞŶƚŝĂůĨŽƌљ Potential for n lurasidone, antipsychotic antipsychotic antipsychotic modafinil, quetiapine, pimozide, Lurasidone & Lurasidone & paliperidone, pimozide are pimozide are risperidone, contraindicated contraindicated ziprasidone xClozapine, Potential for n Potential for p Cobicistat-boosted olanzapine antipsychotic antipsychotic PIs: potential for n antipsychotic Ritonavir-boosted W/Ɛ͗ƉŽƚĞŶƚŝĂůĨŽƌљ PSYCHOTROPICS INSTIs NNRTIs PIs RTI xBICTEGRAVIR xELVITEGRAVIR/ x DORAVIRINE x EFAVIRENZ xATAZANAVIR • TENOFOVIR • TENOFOVIR (Biktarvy) COBICISTAT (Pifeltro, (Sustiva, Atripla) (Reyataz/Norvir, ALAFENAMIDE, DISOPROXIL, TDF (Stribild, Genvoya) Delstrigo) Evotaz) TAF (Descovy, (Viread,Truvada, DOLUTEGRAVIR ETRAVIRINE x x Biktarvy, Genvoya, Atripla, Complera, (Tivicay, Triumeq, RILPIVIRINE (Intelence) DARUNAVIR x x Odefsey, Symtuza) Delstrigo, Stribild) Juluca) (Edurant, (Prezista/Norvir, x NEVIRAPINE Complera, Prezcobix, x RALTEGRAVIR (Viramune) •ABACAVIR (Kivexa, Odefsey, Juluca) Symtuza) (Isentress) Ziagen, Triumeq) xLOPINAVIR (Kaletra) olanzapine and nͬљ clozapine xModafinil Dolutegravir, Potential for љ Potential for љ Potential for љ Potential for љ PIs Potential for љ raltegravir elvitegravir NNRTI NNRTI TAF Potential for љ bictegravir Legend: No dose adjustment required. Use combination with caution. Adjustment in drug dose or frequency or additional/more frequent monitoring may be required. May wish to consult with a pharmacist knowledgeable in HIV drug interactions. Contraindicated/avoid combination. PSYCHOTROPICS Mechanism of Drug Interactions, Management and Monitoring Class Mechanism of Interaction Main Interacting ARVs Management Monitoring Benzodiazepines Inhibition of CYP3A4 Ritonavir and cobicistat- Contraindicated. Use (midazolam, triazolam) boosted protease inhibitors alternate benzodiazepine. and elvitegravir Inhibition of mixed CYP Ritonavir and cobicistat- Adjust benzodiazepine dose Benzodiazepine toxicity: (Alprazolam, bromazepam, boosted protease inhibitors according to ataxia, dizziness, buspirone, clonazepam, and elvitegravir. response/toxicity. Other drowsiness, fatigue, muscle estazolam, eszopiclone, benzodiazepines may be weakness, slowed reaction flurazepam, diazepam, used without dose nitrazepam, zolpidem, adjustment. zopiclone) Lorazepam, oxazepam, May be used with all ARVs May use without dose temazepam adjustment Antidepressants Inhibition of mixed CYP Ritonavir and cobicistat- Adjust antidepressant dose Antidepressant toxicity: pathways (citalopram, boosted protease inhibitors according to anticholinergic effects, escitalopram, fluoxetine, and elvitegravir response/toxicity. Other orthostatic hypotension, sertraline, venlafaxine, antidepressants may be used tachycardia, agitation, desvenlafaxine, trazodone, without dose adjustment. headache, somnolence, mirtazapine) dizziness, diarrhea, excessive sweating, weight gain. Induction of mixed CYP Efavirenz, etravirine, Adjust antidepressant dose Antidepressant efficacy pathways pathways nevirapine according to response. (fluoxetine, sertraline, Other antidepressants may trazodone, reboxetine, be used without dose mirtazapine) adjustment. Induction of CYP2B6 Ritonavir-boosted protease Adjust antidepressant dose Antidepressant efficacy (Bupropion) inhibitors, efavirenz, according to response nevirapine (maximum 300 mg daily). Induction of CYP3A4 (St. Dolutegravir, Bictegravir, Contraindicated with most John’s wort) elvitegravir/cobicistat, all PIs antiretrovirals and NNRTIs and Tenofovir Alafenamide PSYCHOTROPICS Class Mechanism of Interaction Main Interacting ARVs Management Monitoring Antipsychotics Inhibition of mixed CYP Ritonavir and cobicistat- Adjust antipsychotic dose Antipsychotic toxicity: pathways (aripiprazole, boosted protease inhibitors according to somnolence, sweating, chest buspirone, lurasidone, and elvitegravir response/toxicity. pain, tachycardia, dizziness, modafinil, quetiapine, insomnia, headache, pimozide, paliperidone, nausea, diarrhea, dry risperidone, ziprasidone) mouth, numbness, weight gain Induction of mixed CYP Efavirenz, etravirine, Adjust antipsychotic dose Antipsychotic efficacy pathways (aripiprazole, nevirapine according to response buspirone, lurasidone, modafinil, quetiapine, pimozide, paliperidone, risperidone, ziprasidone) Induction of CYP1A2 Ritonavir-boosted protease Adjust antipsychotic dose Antipsychotic efficacy (Clozapine, olanzapine) inhibitors according to response. Modafinil Induction of CYP3A4 Most ARVS except for Consider non-interacting Antiretroviral efficacy dolutegravir, raltegravir, TDF ARV regimen if possible. and abacavir. PSYCHOTROPICS ô+,%#+#,2ô2--*ô$-0 '«5 "03%̞"03%ô',2#0!2'-,1 Printed with the assistance of an unrestricted educational grant from: ฀฀฀฀฀฀฀฀ ฀฀฀฀฀฀฀฀ ฀฀฀฀฀.
Load more

Recommended publications
  • <I>Efavirenz</I>, New Therapeutic Agents for AIDS
    CONFERENCE REPORTS 295 CHIMIA 1999. 53. NO.6 CONFERENCE REPORTS Chimia 53 (1999) 295-304 © Neue Schweizerische Chemische Gesellschaft ISSN 0009-4293 Second Swiss/German Meeting on Medicinal Chemistry Fruhjahrsversammlung 1999 der Neuen Schweizerischen Chemischen Gesellschaft (NSCG) 22./23. Marz 1999, Basel Vier Mini-Symposia uber Virologie, Multidrug Resistance, Immunologie und Gene Therapie Organisiert von der Sektion Medizinische Ghemie der NSGG, der Fachgruppe fUr Medizinische Chemie der GDGh und der Basler Chemischen Gesellschatt mit Unterstutzung der Pharmazeutischen Industrie. Report by the Research Team of G. Folkers' 'Correspondence: Prof. Dr. G. Folkers Department of Pharmacy Winterthurerstrasse 190 CH-8057Zi.irich E-Mail: [email protected] Discovery of Indinavir and Efavirenz, New Therapeutic Agents for AIDS Terry A. Lyle, Merck Research Laboratories, West Point, PA, USA For the treatment of HIV infection, two enzymes are of major interest: The HIV-l Protease (PR) and the Reverse- Tran- scriptase (RT). The HIV -Protease, an aspartic-acid pro- tease active as a dimer, is responsible for H 0 the cleavage of polypeptides assembled at o N~' the cell membrane. The inhibition of the Y I( ; N 1\ 0 = H protease-mediated cleavage of the viral "0 o o o precursor polyproteins results in the pro- duction of noninfectious progeny viral par- ticles. The development of lndinavir start- ed with screening a collection of renin inhibitors. A seven-amino-acid analog 1 1 which contains the hydroxyethylene tran- CONFERENCE REPORTS 296 CHIMIA 1999, 53. No.6 prevents the spread of the virus. Different nucleoside inhibitors like AZT, ddI, ddC, d4T and 3TC are already known, but new QH non-nucleoside inhibitors (NNRTI) are U'O developed to decrease the cytotoxicity and N : to improve the selectivity of the viral polymerases vs.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Isoflurane Produces Antidepressant Effects and Induces Trkb Signaling in Rodents
    bioRxiv preprint doi: https://doi.org/10.1101/084525; this version posted July 11, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Isoflurane produces antidepressant effects and induces TrkB signaling in rodents Hanna Antilaa, Maria Ryazantsevaa,b, Dina Popovaa, Pia Sipiläa, Ramon Guiradoa, Samuel Kohtalaa,b, Ipek Yalcinc, Jesse Lindholma, Liisa Vesaa, Vinicius Satod, Joshua Cordeirae, Henri Autioa, Mikhail Kislina, Maribel Riose, Sâmia Jocad, Plinio Casarottoa, Leonard Khirouga, Sari Lauria,b, Tomi Tairaa,f, Eero Castréna* and Tomi Rantamäkia,b* aNeuroscience Center, P.O. Box 56, FI-00014 University of Helsinki, Helsinki, Finland. bDivision of Physiology and Neuroscience, Department of Biosciences, Faculty of Biological and Environmental Sciences, P.O. Box 66, FI-00014 University of Helsinki, Helsinki, Finland. cInstitut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, FR-67084 Strasbourg Cedex, France. dSchool of Pharmaceutical Sciences of Ribeirão Preto 14040-903, Brazil. eTufts University, Boston, MA, USA. fDepartment of Veterinary Biosciences, Faculty of Veterinary Medicine P.O. Box 66, FI-00014 University of Helsinki, Helsinki, Finland. *To whom correspondence should be addressed at: Eero Castrén ([email protected]) or Tomi Rantamäki ([email protected]) A brief burst-suppressing isoflurane anesthesia has been shown to rapidly alleviate symptoms of depression in a subset of patients, but the neurobiological basis of these observations remains obscure. We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3β (GSK3β).
    [Show full text]
  • Sustiva, INN-Efavirenz
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT SUSTIVA 50 mg hard capsules SUSTIVA 100 mg hard capsules SUSTIVA 200 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION SUSTIVA 50 mg hard capsules Each hard capsule contains 50 mg of efavirenz. Excipient with known effect Each hard capsule contains 28.5 mg of lactose (as monohydrate). SUSTIVA 100 mg hard capsules Each hard capsule contains 100 mg of efavirenz. Excipient with known effect Each hard capsule contains 57.0 mg of lactose (as monohydrate). SUSTIVA 200 mg hard capsules Each hard capsule contains 200 mg of efavirenz. Excipient with known effect Each hard capsule contains 114.0 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule SUSTIVA 50 mg hard capsules Dark yellow and white, printed with "SUSTIVA" on the dark yellow cap and "50 mg" on the white body. SUSTIVA 100 mg hard capsules White, printed with "SUSTIVA" on the body and "100 mg" on the cap. SUSTIVA 200 mg hard capsules Dark yellow, printed with "SUSTIVA" on the body and "200 mg" on the cap. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications SUSTIVA is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV- 1) infected adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg. SUSTIVA has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease inhibitor (PI) containing regimens.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Efavirenz) Capsules and Tablets 3 Rx Only
    1 SUSTIVA® 2 (efavirenz) capsules and tablets 3 Rx only 4 DESCRIPTION 5 SUSTIVA® (efavirenz) is a human immunodeficiency virus type 1 (HIV-1) specific, non- 6 nucleoside, reverse transcriptase inhibitor (NNRTI). 7 Capsules: SUSTIVA is available as capsules for oral administration containing either 8 50 mg, 100 mg, or 200 mg of efavirenz and the following inactive ingredients: lactose 9 monohydrate, magnesium stearate, sodium lauryl sulfate, and sodium starch glycolate. 10 The capsule shell contains the following inactive ingredients and dyes: gelatin, sodium 11 lauryl sulfate, titanium dioxide, and/or yellow iron oxide. The capsule shells may also 12 contain silicon dioxide. The capsules are printed with ink containing carmine 40 blue, 13 FD&C Blue No. 2, and titanium dioxide. 14 Tablets: SUSTIVA is available as film-coated tablets for oral administration containing 15 600 mg of efavirenz and the following inactive ingredients: croscarmellose sodium, 16 hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline 17 cellulose, and sodium lauryl sulfate. The film coating contains Opadry® Yellow and 18 Opadry® Clear. The tablets are polished with carnauba wax and printed with purple ink, 19 Opacode® WB. 20 Efavirenz is chemically described as (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4- 21 (trifluoromethyl)-2H-3,1-benzoxazin-2-one. 22 Its empirical formula is C14H9ClF3NO2 and its structural formula is: 1 of 45 Approved v2.0 F C 3 Cl O NO 23 H 24 Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. 25 It is practically insoluble in water (<10 µg/mL).
    [Show full text]
  • SUSTIVA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Embryo-Fetal Toxicity: Avoid administration in the first trimester of These highlights do not include all the information needed to use pregnancy as fetal harm may occur. (5.6, 8.1) SUSTIVA safely and effectively. See full prescribing information for • Hepatotoxicity: Monitor liver function tests before and during treatment in SUSTIVA. patients with underlying hepatic disease, including hepatitis B or C SUSTIVA (efavirenz) capsules for oral use coinfection, marked transaminase elevations, or who are taking medications associated with liver toxicity. Among reported cases of SUSTIVA (efavirenz) tablets for oral use hepatic failure, a few occurred in patients with no pre-existing hepatic Initial U.S. Approval: 1998 disease. (5.8, 6.1, 8.6) ---------------------------INDICATIONS AND USAGE---------------------------­ • Rash: Rash usually begins within 1-2 weeks after initiating therapy and SUSTIVA is a non-nucleoside reverse transcriptase inhibitor indicated in resolves within 4 weeks. Discontinue if severe rash develops. (5.7, 6.1, 17) combination with other antiretroviral agents for the treatment of human • Convulsions: Use caution in patients with a history of seizures. (5.9) immunodeficiency virus type 1 infection in adults and in pediatric patients at • Lipids: Total cholesterol and triglyceride elevations. Monitor before least 3 months old and weighing at least 3.5 kg. (1) therapy and periodically thereafter. (5.10) • Immune reconstitution syndrome: May necessitate further evaluation and -----------------------DOSAGE AND ADMINISTRATION----------------------­ treatment. (5.11) • SUSTIVA should be taken orally once daily on an empty stomach, • Redistribution/accumulation of body fat: Observed in patients receiving preferably at bedtime. (2) antiretroviral therapy. (5.12, 17) • Recommended adult dose: 600 mg.
    [Show full text]
  • Effects of in Vitro Amitriptyline, Fluoxetine, Tranylcypromine and Venlafaxine on Saphenous Vein Grafts
    ORIGINAL ARTICLE Braz J Cardiovasc Surg 2019;34(3):290-6 Effects of in vitro Amitriptyline, Fluoxetine, Tranylcypromine and Venlafaxine on Saphenous Vein Grafts Melek Akinci1, MD; Cetin Hakan Karadag2, MD; Serhat Huseyin3, MD; Cagatay Oltulu4, MD; Suat Canbaz3, MD; Ozgur Gunduz2, MD; Ruhan Deniz Topuz2, MD DOI: 10.21470/1678-9741-2018-0338 Abstract Objective: In this study, we aimed to examine the effects of (Log M) was 74.6%, the response at -6.32 (Log M) was 75.5%. amitriptyline, fluoxetine, tranylcypromine and venlafaxine on While the relaxation response at -6.46 (Log M) of fluoxetine was saphenous vein grafts in coronary artery bypass graft surgeries. 68.02%, the response at -6.02 (Log M) was 72.12%. While the Methods: 59 patients (40 males and 19 females; mean age relaxation response of tranylcypromine at -7.53 (Log M) was 65.1 years, distribution: 45-84 years) who had coronary artery 61.13%, the response at -7.23 (Log M) was 65.53%. While the bypass graft surgery between February 2014 and May 2016 were relaxation response of venlafaxine at -6.21 (Log M) was 29.98%, included in the study. After the saphenous vein grafts with intact the response at -5.90 (Log M) was 32.96%. and denuded endothelium were precontracted with 3×10-6M Conclusion: The maximum relaxation at minimum and phenylephrine, amitriptyline, fluoxetine and tranylcypromine maximum therapeutic concentrations was obtained with were cumulatively added to isolated organ baths in the range of amitriptyline, fluoxetine and tranylcypromine, and the minimum 10-11-3x10-5M, while venlafaxine was added in the range of 10-9- relaxation was obtained with venlafaxine.
    [Show full text]
  • Download PDF Flyer
    REVIEWS IN PHARMACEUTICAL & BIOMEDICAL ANALYSIS Editors: Constantinos K. Zacharis and Paraskevas D. Tzanavaras eBooks End User License Agreement Please read this license agreement carefully before using this eBook. Your use of this eBook/chapter constitutes your agreement to the terms and conditions set forth in this License Agreement. Bentham Science Publishers agrees to grant the user of this eBook/chapter, a non-exclusive, nontransferable license to download and use this eBook/chapter under the following terms and conditions: 1. This eBook/chapter may be downloaded and used by one user on one computer. The user may make one back-up copy of this publication to avoid losing it. The user may not give copies of this publication to others, or make it available for others to copy or download. For a multi-user license contact [email protected] 2. All rights reserved: All content in this publication is copyrighted and Bentham Science Publishers own the copyright. You may not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit any of this publication’s content, in any form by any means, in whole or in part, without the prior written permission from Bentham Science Publishers. 3. The user may print one or more copies/pages of this eBook/chapter for their personal use. The user may not print pages from this eBook/chapter or the entire printed eBook/chapter for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained from the publisher for such requirements.
    [Show full text]
  • Supplementary Material Exploring the Efficiency of UHPLC-Orbitrap MS For
    Supplementary Material Exploring the efficiency of UHPLC-Orbitrap MS for the determination of 20 pharmaceuticals and acesulfame K in hospital and urban wastewaters with the aid of FPSE Maria Kalaboka, Christoforos Chrimatopoulos, Cristina Jiménez-Holgado, Vasiliki Boti, Vasilios Sakkas, * and Triantafyllos Albanis University of Ioannina, Chemistry Department, 45110 Ioannina, Greece; [email protected], [email protected] , [email protected], [email protected], talbanis@uoi,gr, [email protected] * Correspondence: [email protected]; Tel.: +30-2651008303 Table S1: Physicochemical properties and chemical structures of target analytes Molecular Therapeutic Compound Chemical Structure pKa [Ref.] logP Formula class - Artificial Acesulfame C4H5NO4S 2.0 [1] 0.552 Sweetener tricyclic Amitriptiline C20H23N 9.4 [2] 4.81 antidepressant s Psychiatric Carbamazepine C15H12N2O 7.0/13.9 [3] 2.766 Antiepileptic Drugs Psychiatric Clomipramine C19H23ClN2 8.98 [4] 4.883 Antidepressant Drugs Psychiatric Cyclobenzaprine C20H21N 8.47 [5] 4.613 Antidepressant Drugs Non-steroidal anti- Diclofenac C14H11Cl2NO2 4.2 [3] 4.259 inflammatory drug (NSAID) Macrolide Erythromycin C37H66NO12 8.9 [3] 2.596 Antibiotic Antidepressant Fluoxetine C17H18F3NO 10.1 [6] 4.173 Drugs Analgesic-anti- Indomethacin C19H16ClNO4 4.27 [3] 3.53 inflammatory drug Nonsteroidal anti- Mefenamic Acid C15H15NO2 4.2 [7] 5.398 inflammatory drugs (NSAID) Psychiatric Paroxetine C19H20O3NF 9.6 [6] 3.148 Antidepressant Drugs Non-steroidal anti- Salicylic acid C7H6O3 2.3/3.5 [6] 1.977 inflammatory drug (NSAID) Sulfonamide Sulfacetamide C8H10N2O3S 5.4 [8] -0.3 Antibiotic Sulfonamide Sulfamethazine C12H14N4O2S 7.6/2.65 [9] 0.65 Antibiotic Sulfonamide Sulfamethoxazole C10H11N3O3S 5.7/1.6 [9] 0.791 Antibiotic Sulfamethoxy- Sulfonamide C11H12N4O3S 6.7 [9] 0.466 pyridazine Antibiotic 6.24/2.
    [Show full text]
  • Disproportionality Analysis of Antiretrovirals
    Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, March 3–6 2014 Poster #761 Disproportionality Analysis of Antiretrovirals with Suicidality using FDA Adverse Event Reporting System (FAERS) Data Daniel Seekins Andrew Napoli1, John Coumbis2, Jennifer Wood2, Amit Soitkar2, Daniel Seekins1 Bristol-Myers Squibb, Plainsboro, NJ, USA 1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Bristol-Myers Squibb, Hopewell, NJ, USA Email: [email protected] INTRODUCTION Statistical Analysis Suicide Attempt CONSIDERATIONS n A disproportionality analysis was performed for the selected drug and selected AE using the MGPS method Efavirenz (n = 107) Antiretrovirals n Psychiatric events, including depression, suicidal ideation, suicide attempts, and completed Antidepressants Strengths suicide have been reported in patients receiving efavirenz since 19981 Etravirine (n = 4) n The disproportionality measure, Empirical Bayesian Geometric Mean (EBGM), and the EB05 n FAERS is a large, independent, public dataset containing real-world data that can enable corresponding 90% CI (EB05, EB95) were estimated Nevirapine (n = 41) EBGM n Recently, a pooled analysis of four AIDS Clinical Trials Group (ACTG) studies (A5095, A5142, EB95 identification of potential signals for rare AEs A5175, A5202), identified an increased rate of suicidality with efavirenz-containing regimens n The threshold score above which a drug-event disproportionality signal is likely to be present Atazanavir (n = 13) compared to efavirenz-free regimens: is an EB05
    [Show full text]
  • Pharmacokinetics and Pharmacology of Drugs Used in Children
    Drug and Fluid Th erapy SECTION II Pharmacokinetics and Pharmacology of Drugs Used CHAPTER 6 in Children Charles J. Coté, Jerrold Lerman, Robert M. Ward, Ralph A. Lugo, and Nishan Goudsouzian Drug Distribution Propofol Protein Binding Ketamine Body Composition Etomidate Metabolism and Excretion Muscle Relaxants Hepatic Blood Flow Succinylcholine Renal Excretion Intermediate-Acting Nondepolarizing Relaxants Pharmacokinetic Principles and Calculations Atracurium First-Order Kinetics Cisatracurium Half-Life Vecuronium First-Order Single-Compartment Kinetics Rocuronium First-Order Multiple-Compartment Kinetics Clinical Implications When Using Short- and Zero-Order Kinetics Intermediate-Acting Relaxants Apparent Volume of Distribution Long-Acting Nondepolarizing Relaxants Repetitive Dosing and Drug Accumulation Pancuronium Steady State Antagonism of Muscle Relaxants Loading Dose General Principles Central Nervous System Effects Suggamadex The Drug Approval Process, the Package Insert, and Relaxants in Special Situations Drug Labeling Opioids Inhalation Anesthetic Agents Morphine Physicochemical Properties Meperidine Pharmacokinetics of Inhaled Anesthetics Hydromorphone Pharmacodynamics of Inhaled Anesthetics Oxycodone Clinical Effects Methadone Nitrous Oxide Fentanyl Environmental Impact Alfentanil Oxygen Sufentanil Intravenous Anesthetic Agents Remifentanil Barbiturates Butorphanol and Nalbuphine 89 A Practice of Anesthesia for Infants and Children Codeine Antiemetics Tramadol Metoclopramide Nonsteroidal Anti-infl ammatory Agents 5-Hydroxytryptamine
    [Show full text]